{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:35:58Z","timestamp":1790019358932,"version":"4.0.1"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            An understanding of the antibody persistence elicited by a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliovirus vaccine (Tdap-IPV) after adolescent vaccination is important to optimize booster dosing intervals. Our objectives were to compare the safety and immunogenicity of Tdap-IPV coadministered with hepatitis B vaccine (HepB) and sequential administration and evaluate humoral immunity at 3, 5, and 10 years after Tdap-IPV vaccination in adolescents. This phase II randomized, controlled, and open-label study enrolled 280 11- to 14-year-old adolescents with up to 10 years postvaccination follow-up. Group 1 (\n            <jats:italic>n<\/jats:italic>\n            = 145) received Tdap-IPV, followed by a HepB dose 1 month later, and group 2 (\n            <jats:italic>n<\/jats:italic>\n            = 135) received both vaccines simultaneously. No consistent increases in solicited reactions or unsolicited adverse events occurred with coadministration. All vaccinees attained seroprotective antibody levels at \u22650.01 IU\/ml for diphtheria and tetanus, at a \u22651:8 dilution for poliovirus (serotypes 1, 2, and 3), and \u226510 mIU\/ml for hepatitis B at 1 month postvaccination. Clinically relevant immunologic interactions did not occur with coadministration. For pertussis, all participants achieved seropositivity levels (at or above the lower limit of quantitation), and 72.7% to 95.8% had 4-fold increases in pertussis antibodies at 1 month postvaccination. At 10 years postvaccination, the remaining participants (62.8% of the original cohort) maintained seroprotective levels of \u22650.01 IU\/ml for diphtheria and tetanus, a \u22651:8 dilution for all 3 poliovirus serotypes, and 74.1% to 98.2% maintained pertussis seropositivity levels depending on the antigen tested. There were no differences between the groups. These results support the coadministration of Tdap-IPV and HepB to adolescents and suggest that vaccination with Tdap-IPV can offer protection for 10 years after an adolescent booster vaccination.\n          <\/jats:p>","DOI":"10.1128\/cvi.00682-14","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T05:58:17Z","timestamp":1419487097000},"page":"282-290","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["Immunogenicity, Safety, and Antibody Persistence at 3, 5, and 10 Years Postvaccination in Adolescents Randomized to Booster Immunization with a Combined Tetanus, Diphtheria, 5-Component Acellular Pertussis, and Inactivated Poliomyelitis Vaccine Administered with a Hepatitis B Virus Vaccine Concurrently or 1 Month Apart"],"prefix":"10.1128","volume":"22","author":[{"given":"Joanne","family":"Embree","sequence":"first","affiliation":[{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Law","sequence":"additional","affiliation":[{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Voloshen","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Swiftwater, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antigona","family":"Tomovici","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"1690","article-title":"Notifiable diseases and mortality tables","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","unstructured":"Centers for Disease Control and Prevention (CDC). 2011. Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 59:1690\u20131703.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31818a5d69"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000166154.47013.47"},{"key":"e_1_3_2_5_2","first-page":"385","article-title":"Pertussis vaccines: WHO position paper","volume":"40","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 40:385\u2013400.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.147"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2008.05.010"},{"key":"e_1_3_2_8_2","first-page":"517","article-title":"Pertussis Epidemic\u2014Washington, 2012","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). 2012. Pertussis Epidemic\u2014Washington, 2012. MMWR Morb Mortal Wkly Rep 61:517\u2013522.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_9_2","first-page":"ND635","article-title":"Notifiable diseases and mortality tables","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). 2012. Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 61:ND635\u2013ND638.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000256750.07118.ee"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/652281"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268807009041"},{"key":"e_1_3_2_13_2","first-page":"19","article-title":"Statement on alternate adolescent schedule for hepatitis B vaccine (ACS-5). An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI)","volume":"26","author":"National Advisory Committee on Immunization (NACI)","year":"2000","unstructured":"National Advisory Committee on Immunization (NACI). 2000. Statement on alternate adolescent schedule for hepatitis B vaccine (ACS-5). An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Can Commun Dis Rep 26:19\u201320.","journal-title":"Can Commun Dis Rep"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.030"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/421943"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.031"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/655825"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.102"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.025"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.02.013"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.089"},{"key":"e_1_3_2_22_2","volume-title":"Adacel-Polio: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine","author":"Sanofi Pasteur Ltd","year":"2013","unstructured":"Sanofi Pasteur Ltd. 2013. Adacel-Polio: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine. Sanofi Pasteur Ltd., Toronto, Ontario, Canada."},{"key":"e_1_3_2_23_2","volume-title":"Recombivax HB hepatitis B vaccine (recombinant)","author":"Merck Canada, Inc","year":"2012","unstructured":"Merck Canada, Inc. 2012. Recombivax HB hepatitis B vaccine (recombinant). Merck Canada, Inc., Kirkland, Quebec, Canada."},{"key":"e_1_3_2_24_2","volume-title":"The immunological basis for immunization series. Module 4: pertussis: update 2009","author":"World Health Organization Department of Immunization Vaccines and Biologicals","year":"2009","unstructured":"World Health Organization Department of Immunization Vaccines and Biologicals. 2009. The immunological basis for immunization series. Module 4: pertussis: update 2009. World Health Organization, Geneva, Switzerland. http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241599337_eng.pdf."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_3_2_26_2","volume-title":"The immunological basis for immunization series. Module 2: diphtheria: update 2009","author":"World Health Organization Department of Immunization Vaccines and Biologicals","year":"2009","unstructured":"World Health Organization Department of Immunization Vaccines and Biologicals. 2009. The immunological basis for immunization series. Module 2: diphtheria: update 2009. World Health Organization, Geneva, Switzerland. http:\/\/whqlibdoc.who.int\/publications\/2009\/9789241597869_eng.pdf."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200004000-00003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00227-8"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00682-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00682-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:19Z","timestamp":1627591879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00682-14"}},"subtitle":[],"editor":[{"given":"H. F.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/CVI.00682-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00682-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"2014-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}